President Donald Trump told reporters on Monday he is weighing an executive order to reclassify marijuana as a Schedule III substance. The potential action could transform the cannabis market, reduce legal punishments and allow for easier scientific research.TLRY stock is moving. See the chart and price action here. “We are looking at that very strongly,” Trump said in response to reports that he is looking at directing agencies to treat marijuana as a Schedule III drug.Read Next: Elon Musk Prepares SpaceX ...

Bill Schmitt Jr. (C) joins cannabis reform protesters outside the White House to call on U.S. President Joe Biden "to take action on cannabis clemency before the November general election” October 24, 2022 in Washington, DC.Pot stocks failed to light up for a second day on Monday even after President Donald Trump confirmed he's considering an executive order loosening regulations on marijuana.The Amplify Seymour Cannabis ETF (CNBS) took a leg up in afternoon trading after Trump said he was weighing reclassi ...

Core Point - President Donald Trump is considering signing an executive order to reclassify marijuana as a less dangerous drug [1] Group 1 - The potential reclassification of marijuana could impact its legal status and accessibility [1] - This move may influence the cannabis industry, potentially leading to increased investment and market growth [1] - The decision reflects a shift in the government's approach to drug policy, which could have broader implications for public health and safety [1]

Aurora Cannabis Inc. (NASDAQ:ACB) ranks among the best sin stocks to buy in 2026. Aurora Cannabis Inc. (NASDAQ:ACB) has recently been making significant market growth in Europe and Australia, with the company stating on December 2 that its subsidiary, MedReleaf Australia, has signed a distribution agreement with Leafio, Montu Australia’s wholesale arm. The partnership intends to give medical professionals training materials while expanding patient access to medical cannabis products throughout Australia. ...

Group 1: Canadian Tech Sector - Celestica Inc. shares fell 12.92% due to "AI skepticism," impacting the overall index negatively [1] Group 2: Canadian Cannabis Companies - Tilray Brands Inc. shares increased by 44.35%, Canopy Growth Corp. shares rose by 52.87%, Aurora Cannabis Inc. shares were up 19.04%, and Organigram Global Inc. shares increased by 16.81% following reports of potential easing of federal restrictions on cannabis by U.S. President Donald Trump [2] - The aggressive legalization in the U.S. could revitalize Canadian cannabis stocks, which had previously seen significant declines [2] Group 3: Canadian Economic Indicators - Investors are anticipating November inflation data, with a consensus forecast of 2.3% headline inflation, which will provide insights into the Canadian economy's health [3] - The Bank of Canada policy rate is currently at 2.25% [3] Group 4: U.S. Market Performance - Broadcom's shares dropped 11.4% despite reporting stronger-than-expected profits, contributing to market concerns about the AI sector [4] - Oracle's shares fell nearly 11% after reporting better-than-expected profits, raising fears about high valuations in the AI market [5] - The S&P 500 index was notably affected by declines in Broadcom and Nvidia, with Oracle's results causing disappointment among investors [5] Group 5: Market Indices and Commodities - The Dow Jones industrial average decreased by 245.96 points, the S&P 500 index fell by 73.59 points, and the Nasdaq composite dropped by 398.69 points [6] - The Canadian dollar traded at 72.63 cents US, and crude oil prices fell by 16 cents to US$57.44 per barrel, while gold prices increased by US$15.30 to US$4,328.30 per ounce [6]

Cannabis stocks surged Friday in the wake of reports that President Trump is preparing to reclassify marijuana under federal law — a long-awaited shift that investors say could loosen restrictions and revive a battered industry.Traders piled into pot firms on expectations that Trump will move cannabis from Schedule I to Schedule III under the Controlled Substances Act, a step that would treat marijuana as less dangerous and acknowledge it as acceptable for medical use.The rally marked one of the biggest sin ...

Core Viewpoint - President Trump is reportedly considering an order to reschedule marijuana from a Schedule I to a Schedule III drug, which could significantly impact the cannabis industry by allowing companies to access banking services and reducing tax burdens [1][2][3] Industry Impact - Rescheduling marijuana would not legalize it but would allow cannabis companies to operate more freely, potentially leading to a different tax status, reducing tax rates from approximately 40% to around 10-15% [3][9] - The cannabis market is currently experiencing volatility, with some stocks, like MISO, seeing increases of up to 38% due to speculation around this potential order [5][13] Regulatory Process - The Department of Justice (DOJ) and the Drug Enforcement Administration (DEA) are expected to restart the rulemaking process for rescheduling, which is about 70% complete and could be finalized by the first half of next year if expedited [6][17] - There is uncertainty regarding the specifics of the order, as it may face legal challenges if it does not provide clear directives for rescheduling [7][9] Market Sentiment - Retail sentiment is currently high in the cannabis market, with Canadian pot equities also seeing increases of around 30%, although this does not directly apply to U.S. companies [13][14] - The potential for consolidation in the cannabis industry is anticipated as regulatory frameworks improve, with larger companies likely to acquire smaller ones [16][18]

Core Insights - The U.S. marijuana industry has faced stagnation due to federal inaction on reclassification or decriminalization, with cannabis classified as a Schedule I drug, limiting research and access to banking services [1][2] - President Trump's potential executive order to reclassify marijuana as a Schedule III substance could significantly impact the industry, attracting institutional investors and improving banking access [3][5][8] Industry Overview - The U.S. marijuana market is valued at approximately $32 billion, with state-level sales exceeding $30 billion annually, yet investors remain cautious due to the Schedule I classification [3][8] - Reclassification could double industry growth rates to 20% annually, although full effects may take 12 to 18 months due to rulemaking delays [8] Company Impacts Tilray Brands (TLRY) - Tilray could benefit from eased U.S. entry and the ability to import medical products interstate, with fiscal 2025 revenue reaching $821 million, up 4% [9] - The end of the 280E tax penalty could boost after-tax profits by 40% to 70%, allowing for expansion [10] Canopy Growth (CGC) - Canopy Growth, already profitable in Canadian medical sales, could see significant savings of $50 million to $70 million annually from eased tax burdens, funding U.S. market entry [12][13] - The company aims for a 30% increase in EBITDA by 2027, leveraging its global presence [13] Aurora Cannabis (ACB) - Aurora Cannabis stands to gain from reclassification, which would ease research and distribution of its pharmaceutical-grade products [14] - The company reported a fiscal Q2 2026 net income of $81 million Canadian, with potential for 15% revenue growth [15] Legislative Context - Trump's executive order aims to bypass administrative hearings and expedite marijuana's shift to Schedule III, which recognizes moderate abuse potential and accepted medical value [5][10] - While reclassification does not fully legalize marijuana, it could unlock significant changes in the industry landscape [7][10] Market Sentiment - Following news of the potential executive order, cannabis stocks like Tilray, Canopy Growth, and Aurora Cannabis saw double-digit percentage gains, indicating renewed investor interest [4][6]

If weed becomes legal, will Aurora Cannabis become profitable?Aurora Cannabis (ACB +15.38%) stock leapt 14.5% "higher" (get it? Marijuana? High?) through 11:55 a.m. ET Friday on some positive marijuana news out of the White House.As The Washington Post reports, President Trump wants to legalize marijuana (sort of), and marijuana investors are overjoyed at the prospect. President Trump's Christmas gift to marijuana investorsThe Post cites six separate sources confirming that Trump will issue an executive or ...

Cannabis stocks like Tillray, Aurora, and the Advisor Shares ETF are all soaring on these reports that the president will move to reclassify marijuana as a less dangerous drug. Our Brandon Gomez has been covering the story for what feels like forever and has more on the timing of this news. Hey, Brandon. >> Hey, Carl.Yeah, that's right. I feel like we've been here before, right. But with the president wanting to reschedule uh the drug to a new classification, now it is currently scheduled as schedule one.No ...